Ascletis Pharma Presents Preclinical Results for Weight Management Drugs at ObesityWeek 2026
MT Newswires Live
Yesterday
Ascletis Pharma (HKG:1672) presented key preclinical results for ASC48, ASC30_48 fixed dose combination, and ASC37 at ObesityWeek 2026, a Monday bourse filing showed.
The two poster presentations feature in vitro activity and oral pharmacokinetics of ASC48; weight loss data for ASC30_48; and extended pharmacokinetics, in vitro insulin secretion activity, and weight-loss activity of ASC37.
ObesityWeek 2026 is being held in Washington, DC, from Nov. 14 to 17.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.